RG
ZNTL icon

Redmile Group’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Redmile Group’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-425,480
Closed -$22.6M – 87
2021
Q2 		$22.6M Sell
425,480
-1,795,564
-81% -$96.2M 0.34% 59
2021
Q1 		$96.4M Sell
2,221,044
-195,362
-8% -$8.41M 1.36% 24
2020
Q4 		$126M Sell
2,416,406
-16,002
-0.7% -$722K 1.52% 21
2020
Q3 		$79.5M Buy
2,432,408
+771,203
+46% +$27M 1.46% 22
2020
Q2 		$79.8M Buy
+1,661,205
New +$63.7M 1.47% 20

Other funds holding ZNTL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group's ZNTL Position: Q3 2021 in Review

Redmile Group sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2021, closing a stake of 425,480 shares — an estimated $22.6M sold.

Redmile Group first reported a position in ZNTL in Q2 2020 and held it in 5 quarters. The position peaked at $126M in Q4 2020. 116 funds tracked by Wall St. Rank hold ZNTL as of Q3 2021.

  • Redmile Group reported no remaining Zentalis Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Redmile Group sold 425,480 Zentalis Pharmaceuticals shares in Q3 2021, an estimated $22.6M.
  • Redmile Group first reported a position in Zentalis Pharmaceuticals in Q2 2020 and held it in 5 quarters.
  • Redmile Group's Zentalis Pharmaceuticals position peaked at $126M in Q4 2020.
  • 116 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2021.

Based on Redmile Group's 13F filing for Q3 2021, filed 15 Nov 2021.